Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough blood cancers: experimental drug HRS-3738 enters human testing

NCT ID NCT05363800

Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called HRS-3738 in people with two types of blood cancer—non-Hodgkin's lymphoma and multiple myeloma—that have returned or not improved after prior treatments. The main goals are to find a safe dose and check how well the drug works. About 74 adults will take part across multiple centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

74 people

The number who actually took part.

Started

Jun 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Active multiple myeloma in accordance with IMWG criteria，or histopathologically and immunohistochemically confirmed non-Hodgkin's lymphoma in accordance with the 2016 WHO Classification of lymphoid neoplasias. 2. Recurred or did not alleviate after the previous treatment. 3. Have at least one measurable lesion. 4. With a life expectancy of ≥3 months. 5. Male or female ≥ 18 years old. 6. ECOG performance status of 0-1. 7. Subjects must voluntarily agree to participate in the trial and sign a written informed consent form. Exclusion Criteria: 1. Amyloidosis, plasma cell leukemia. 2. Corrected serum calcium\>3.4mmol/L(13.5mg/dl). 3. Presence of metastasis to central nervous system. 4. Treatment of other investigational products. 5. Major surgical therapy within 28 days prior to the date of signature of informed consent form, or expected major surgery during the study. 6. Known history of hypersensitivity to any components of HRS-3738. 7. Other factors that may affect the study results or lead to forced termination of the study early as judged by investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent and refractory multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-Hodgkin lymphoma plasma cell myeloma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrent and refractory non-Hodgkin's lymphoma and multiple myeloma

Contacts and locations

Locations

  • Henan cancer Hospital

    Zhengzhou, Henan, 450000, China

  • Sheng Jing Hospital of China Medical University

    Shengyang, Liaoning, 110004, China

  • Zhejiang University School of Medicine The First Affiliated Hospital

    Hangzhou, Zhejiang, 310003, China